Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Inclusion Criteria: 1. Locally advanced or metastatic (stage ШB-Ⅳ, 8th AJCC) NSCLC confirmed by histology or cytology; 2. The result of EGFR 20ins is positive detected by tissue, blood, pleural fluid or cerebrospinal fluid; 3. Have received osimertinib treatment after detection of EGFR 20ins; 4. Age of 18 years or above; 5. Information about tumor outcome evaluation is required at least once after osimertinib treatment (such as tumor imaging data, description of efficacy evaluation in medical records, etc.). Exclusion Criteria: 1. Previously treated with JMT101 (Patients will be included if osimertinib treatment is before JMT101 treatment); 2. Patients harboring EGFR exon20 insertion mutation and also have other EGFR TKI-sensitizing EGFR mutations, such as G719X mutation in exon 18, exon 19 deletion mutation (19 del), exon 20 T790M or S768I mutation, exon 21 L858R mutation, or L861Q mutation.